# Acute myeloid leukaemia

Source: https://onco.cc/cancers/aml/  
OnCo record `aml` (Cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived.

## Summary

Acute myeloid leukaemia is a cancer of immature myeloid cells that floods the marrow and blood within weeks. It is defined molecularly: WHO 2022 and ICC 2022 classify by driver genetics, and ELN 2022 assigns favourable, intermediate, or adverse risk from NPM1, CEBPA, core-binding-factor fusions, FLT3, TP53, KMT2A, and myelodysplasia-related mutations. Median age at diagnosis is 68, and outcomes diverge sharply by age and fitness.

Treatment split into two paradigms. Fit patients receive intensive 7+3 induction (unchanged since 1973) with a targeted add-on chosen by genetics: midostaurin or quizartinib for FLT3, gemtuzumab ozogamicin for CD33+ favourable and intermediate risk, CPX-351 for secondary AML, then high-dose cytarabine consolidation and allogeneic transplant for adverse or MRD-positive disease. Unfit patients, once offered only supportive care, now receive venetoclax with azacitidine (VIALE-A) or, since May 2026, an all-oral regimen with decitabine-cedazuridine; IDH1-mutated patients may receive ivosidenib-azacitidine (AGILE). Relapse is treated by genotype: gilteritinib (FLT3), ivosidenib, olutasidenib or enasidenib (IDH), and the new menin inhibitors revumenib and ziftomenib (NPM1-mutated or KMT2A-rearranged), with transplant as the consolidating cure.

Measurable residual disease by flow cytometry, NPM1 qPCR, or error-corrected NGS now decides transplant and maintenance, and platform trials such as myeloMATCH assign therapy from rapid genomics at diagnosis. The unsolved problems are TP53-mutated and complex-karyotype AML, where every new class has failed so far, relapse after transplant, early death from infection in older patients, and the cost and logistics of the increasingly individualised pathway.

## Fields

- Kind: Cancer
- Last checked: 2026-09-04
- Tags: heme
- Group: haematologic
- Burden: About 20,000 new cases a year in the US and 120,000 worldwide; median age 68. Genotype-directed drugs and venetoclax combinations have made most patients treatable, and outcomes diverge by genetics. 5-year survival is roughly 30% overall, above 60% in favourable-risk younger adults and below 10% in TP53-mutated disease.
- Subtypes: AML with defining genetic abnormalities (WHO 2022): NPM1-mutated, CEBPA bZIP, RUNX1::RUNX1T1, CBFB::MYH11, KMT2A-rearranged, DEK::NUP214, BCR::ABL1, MECOM; Acute promyelocytic leukaemia (PML::RARA), curable without chemotherapy in most cases (ATRA + arsenic); AML, myelodysplasia-related (mutations in ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, ZRSR2 or MDS-type cytogenetics); TP53-mutated AML / complex karyotype (adverse; ~10-15%); Therapy-related AML after alkylators or topoisomerase II inhibitors; FLT3-ITD or FLT3-TKD (30%; targetable); IDH1 or IDH2-mutated (15-20%; targetable); Blastic plasmacytoid dendritic cell neoplasm (CD123-high; related entity)
- Biomarkers: FLT3-ITD/TKD; NPM1; IDH1/2; KMT2A; TP53; CD33; ELN risk; MRD; ELN 2022 genetic risk group; FLT3-ITD and TKD (midostaurin, quizartinib, gilteritinib); NPM1 (favourable risk without FLT3-ITD; MRD marker; menin inhibitor eligibility); IDH1 / IDH2 (ivosidenib, olutasidenib, enasidenib); KMT2A rearrangement (revumenib); TP53 and complex karyotype (adverse; venetoclax less effective); CD33 (gemtuzumab), CD123 (tagraxofusp, pivekimab); Measurable residual disease (flow, NPM1 qPCR, NGS) after cycles 2 and before transplant; Karyotype/FISH at diagnosis; Myelodysplasia-related mutation set

## Sections of this record

The page is a hub with ten sections in reading order; large sections have their own page. The same plan as JSON: https://onco.cc/api/v1/cancers/aml/sections.json

- Overview (on the hub): The TL;DR, the family this cancer belongs to, the organ, who gets it and what the state of the art is. https://onco.cc/cancers/aml/#overview [7 subtypes, 8 state-of-the-art points]
- What it is (on the hub): Anatomy, the subtypes and how they differ, how it is staged, and where advanced disease spreads. https://onco.cc/cancers/aml/#what-it-is [15 subtypes]
- Finding it (on the hub): How it shows itself, how it is confirmed, what screening exists, and the biomarkers clinicians test for. https://onco.cc/cancers/aml/#finding-it [18 biomarkers, 15 prevalence rows]
- Treating it (on the hub): The standard of care by setting, the medicines, surgery and radiotherapy named in it, and the regimens behind them. https://onco.cc/cancers/aml/#treating-it [14 settings, 4 regimens, 11 decisions with options]
- Evidence (own page): Trials recruiting now, the landmark trials, the key papers and what they mean, the latest literature, and the milestones year by year. https://onco.cc/cancers/aml/evidence/ [84 trials, 11 key papers, 19 milestones]
- The science (own page): The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models. https://onco.cc/cancers/aml/science/ [106 targets, 9 pathways, 9 preclinical models]
- Where you are (own page): Cases by country, the UK and NHS pathway and other country lenses, and the expert centres with trials on record. https://onco.cc/cancers/aml/where-you-are/ [50 centres]
- Living with it (own page): The decisions you may face, the aids that walk through them, the warnings on record, the first sixty days and the questions to ask. https://onco.cc/cancers/aml/living-with-it/ [42 questions, 6 red cards]
- What is coming (own page): Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record. https://onco.cc/cancers/aml/coming/ [50 medicines, 84 trials, 7 ideas, 9 open problems]
- Data (own page): Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked. https://onco.cc/cancers/aml/data/ [524 connected records]

## Standard of care

- Fit: 7+3 ± targeted agent; consolidation; allogeneic transplant by risk. ([Gemtuzumab ozogamicin](https://onco.cc/drugs/gemtuzumab-ozogamicin/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/))
- Unfit: Azacitidine + venetoclax. ([Venetoclax](https://onco.cc/drugs/venetoclax/))
- Relapsed: Genotype-directed: gilteritinib, IDH inhibitors, menin inhibitors; transplant. ([Revumenib](https://onco.cc/drugs/revumenib/))
- Diagnosis and risk assignment: Marrow morphology, flow, karyotype/FISH, rapid FLT3/NPM1/IDH testing (results within days), NGS panel; ELN 2022 risk; fitness assessment. Menin-inhibitor and FLT3-inhibitor eligibility depends on these results. ([Cytogenetics and FISH](https://onco.cc/technologies/cytogenetics-fish/), [Comprehensive genomic profiling](https://onco.cc/technologies/cgp/), [ELN 2022 risk classification](https://onco.cc/terms/eln-risk/), [Multiparameter flow cytometry MRD](https://onco.cc/technologies/flow-cytometry-mrd/))
- Fit, FLT3-mutated: 7+3 plus midostaurin (ITD or TKD) or quizartinib (ITD only), consolidation with continued inhibitor, allogeneic transplant for most FLT3-ITD in CR1, post-transplant FLT3-inhibitor maintenance if MRD-positive. ([Cytarabine + anthracycline ('7+3')](https://onco.cc/drugs/cytarabine-7-3/), [Midostaurin](https://onco.cc/drugs/midostaurin/), [Quizartinib](https://onco.cc/drugs/quizartinib/), [RATIFY (CALGB 10603)](https://onco.cc/trials/ratify/), [QuANTUM-First](https://onco.cc/trials/quantum-first/), [Allogeneic stem cell transplantation](https://onco.cc/technologies/allogeneic-hsct/))
- Fit, favourable or intermediate risk, CD33-positive: 7+3 plus fractionated gemtuzumab ozogamicin (ALFA-0701); high-dose cytarabine consolidation; MRD-guided transplant for intermediate risk. ([Gemtuzumab ozogamicin](https://onco.cc/drugs/gemtuzumab-ozogamicin/), [ALFA-0701](https://onco.cc/trials/alfa-0701/), [Cytarabine + anthracycline ('7+3')](https://onco.cc/drugs/cytarabine-7-3/))
- Fit, secondary or therapy-related AML: CPX-351 induction (Study 301) then transplant in CR1; alternatives include 7+3 or venetoclax-based therapy in trials. ([CPX-351 (liposomal daunorubicin-cytarabine)](https://onco.cc/drugs/cpx-351/), [CPX-351 Study 301](https://onco.cc/trials/cpx-351-301/), [Allogeneic stem cell transplantation](https://onco.cc/technologies/allogeneic-hsct/))
- Fit, adverse risk (TP53, complex karyotype, MDS-related): Intensive induction or venetoclax-azacitidine to remission, then allogeneic transplant as the only realistic cure; clinical trial strongly preferred; TP53-mutated disease has no effective targeted therapy after the magrolimab and eprenetapopt failures. ([Allogeneic stem cell transplantation](https://onco.cc/technologies/allogeneic-hsct/), [Venetoclax](https://onco.cc/drugs/venetoclax/), [Azacitidine](https://onco.cc/drugs/azacitidine/), [Magrolimab](https://onco.cc/drugs/magrolimab/))
- Unfit for intensive chemotherapy (most patients over 75): Venetoclax + azacitidine (VIALE-A) or venetoclax + oral decitabine-cedazuridine (ASCERTAIN-V, 2026); ivosidenib + azacitidine if IDH1-mutated (AGILE); low-dose cytarabine + venetoclax as an alternative. Continue until progression; consider transplant in responders who become fit. ([Venetoclax](https://onco.cc/drugs/venetoclax/), [Azacitidine](https://onco.cc/drugs/azacitidine/), [Decitabine + cedazuridine (oral)](https://onco.cc/drugs/decitabine-cedazuridine/), [Ivosidenib](https://onco.cc/drugs/ivosidenib/), [VIALE-A](https://onco.cc/trials/viale-a/), [AGILE](https://onco.cc/trials/agile/), [ASCERTAIN-V](https://onco.cc/trials/ascertain-v/))
- Maintenance after intensive therapy: Oral azacitidine (Onureg) for patients not transplanted (QUAZAR AML-001); FLT3 inhibitor maintenance after transplant in FLT3-ITD (MORPHO for MRD-positive); menin inhibitor maintenance in trials. ([Azacitidine](https://onco.cc/drugs/azacitidine/), [Gilteritinib](https://onco.cc/drugs/gilteritinib/), [Quizartinib](https://onco.cc/drugs/quizartinib/), [QUAZAR AML-001](https://onco.cc/trials/quazar-aml-001/), [MORPHO](https://onco.cc/trials/morpho/))
- Relapsed or refractory, FLT3-mutated: Gilteritinib monotherapy (ADMIRAL) or gilteritinib + venetoclax/azacitidine, then transplant; quizartinib in Japan. ([Gilteritinib](https://onco.cc/drugs/gilteritinib/), [ADMIRAL](https://onco.cc/trials/admiral/), [Allogeneic stem cell transplantation](https://onco.cc/technologies/allogeneic-hsct/))
- Relapsed or refractory, IDH-mutated: Ivosidenib or olutasidenib (IDH1), enasidenib (IDH2), often with azacitidine or venetoclax; differentiation-syndrome monitoring. ([Ivosidenib](https://onco.cc/drugs/ivosidenib/), [Olutasidenib](https://onco.cc/drugs/olutasidenib/), [Enasidenib](https://onco.cc/drugs/enasidenib/), [Differentiation syndrome](https://onco.cc/terms/differentiation-syndrome/))
- Relapsed or refractory, NPM1-mutated or KMT2A-rearranged: Menin inhibitor: revumenib (KMT2Ar 2024; NPM1 2025) or ziftomenib (NPM1, November 2025), as a bridge to transplant; triplets with venetoclax-azacitidine in trials. ([Revumenib](https://onco.cc/drugs/revumenib/), [Ziftomenib](https://onco.cc/drugs/ziftomenib/), [AUGMENT-101](https://onco.cc/trials/augment-101/), [KOMET-001](https://onco.cc/trials/komet-001/), [Menin inhibitor + venetoclax + azacitidine](https://onco.cc/pairings/menin-plus-venetoclax-hma/))
- Acute promyelocytic leukaemia: ATRA + arsenic trioxide without chemotherapy for standard risk (cure >95%); ATRA + arsenic + idarubicin or gemtuzumab for high risk. Differentiation syndrome prophylaxis. ([Differentiation syndrome](https://onco.cc/terms/differentiation-syndrome/))

## State of the art

- Menin inhibitors.
- Venetoclax combinations.
- Genotype-directed induction: FLT3 inhibitors (two positive phase 3 trials), gemtuzumab for CD33+ favourable/intermediate risk, CPX-351 for secondary AML.
- Venetoclax + hypomethylating agent made unfit AML treatable, and since May 2026 the regimen can be fully oral.
- Menin inhibitors (revumenib 2024/2025, ziftomenib 2025) opened NPM1-mutated and KMT2A-rearranged leukaemia, ~40% of adult AML, to a new drug class within one year.
- MRD by flow and molecular methods now guides transplant, maintenance, and pre-emptive therapy; ELN 2021 MRD standards are in routine use.
- Platform trials (myeloMATCH) assign therapy from rapid genomics at diagnosis and re-assign at each MRD checkpoint.
- Allogeneic transplant is safer (post-transplant cyclophosphamide, haploidentical donors) and increasingly followed by targeted maintenance.

## Open problems

- TP53-mutant AML: no drug class has yet improved survival, so it is the priority for new mechanisms.
- Older patients.
- TP53-mutated and complex-karyotype AML: no class has improved survival; magrolimab (CD47) and eprenetapopt (p53 reactivator) both failed in phase 3.
- Relapse after allogeneic transplant is the main way treatment fails; which maintenance (FLT3, menin, azacitidine) helps whom is unresolved.
- Menin-inhibitor resistance through MEN1 mutations appears within months in a third of relapsing patients; combinations and next-generation inhibitors are needed.
- Infections and low blood counts early in venetoclax-based therapy are the main risk in the very old; optimal venetoclax duration is untested in randomised trials.
- MRD thresholds and assays are not harmonised across labs, and CHIP-associated mutations confound NGS MRD.
- Whether triplets (menin or FLT3 inhibitor + venetoclax + HMA) improve survival over doublets, and at what toxicity, awaits phase 3.
- Access: rapid genomics within 72 hours and menin/FLT3 inhibitors are unavailable in most low- and middle-income settings.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Acute_myeloid_leukemia
- ELN 2022 recommendations: https://ashpublications.org/blood/article/140/12/1345/485817
- NCCN AML guidelines: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1411

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Acute myeloid leukaemia in children](https://onco.cc/cancers/aml-paediatric/), [Acute myeloid leukaemia in older or unfit patients](https://onco.cc/cancers/aml-older-unfit/), [Acute promyelocytic leukaemia](https://onco.cc/cancers/apl/), [Blastic plasmacytoid dendritic cell neoplasm (BPDCN)](https://onco.cc/cancers/bpdcn/), [Childhood cancers (all types)](https://onco.cc/cancers/childhood-cancers/), [Chronic myeloid leukaemia (CML)](https://onco.cc/cancers/cml/), [Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms](https://onco.cc/cancers/cmml/), [FLT3-mutated acute myeloid leukaemia](https://onco.cc/cancers/aml-flt3/), [IDH1- and IDH2-mutated acute myeloid leukaemia](https://onco.cc/cancers/aml-idh/), [Langerhans cell histiocytosis (LCH)](https://onco.cc/cancers/langerhans-cell-histiocytosis/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Mixed-phenotype acute leukaemia](https://onco.cc/cancers/mixed-phenotype-acute-leukaemia/), [Myeloid leukaemia of Down syndrome](https://onco.cc/cancers/myeloid-leukaemia-of-down-syndrome/), [NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia](https://onco.cc/cancers/aml-npm1-kmt2a/), [Secondary and therapy-related acute myeloid leukaemia](https://onco.cc/cancers/aml-secondary/), [Systemic mastocytosis](https://onco.cc/cancers/systemic-mastocytosis/)
- technologies: [Allogeneic (off-the-shelf) cell therapy](https://onco.cc/technologies/allogeneic-cell-therapy/), [Allogeneic stem cell transplantation](https://onco.cc/technologies/allogeneic-hsct/), [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Astatine-211 alpha therapy](https://onco.cc/technologies/astatine-211-alpha-therapy/), [BCL-2 inhibitors](https://onco.cc/technologies/bcl2-inhibitors/), [BH3 profiling (functional apoptosis testing)](https://onco.cc/technologies/bh3-profiling/), [CD47 and SIRP-alpha blockade](https://onco.cc/technologies/cd47-blockade/), [Comprehensive genomic profiling](https://onco.cc/technologies/cgp/), [Cytogenetics and FISH](https://onco.cc/technologies/cytogenetics-fish/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)](https://onco.cc/technologies/epigenetic-drugs/), [Ex vivo drug sensitivity screening in blood cancers (EXALT)](https://onco.cc/technologies/functional-precision-medicine-haematology/), [Flow cytometers](https://onco.cc/technologies/flow-cytometers/), [G8 geriatric screening tool](https://onco.cc/technologies/g8-geriatric-screening/), [Gamma-delta T cell therapy](https://onco.cc/technologies/gamma-delta-t-cell-therapy/), [Hedgehog pathway inhibitors](https://onco.cc/technologies/hedgehog-inhibitors/), [IDH inhibitors](https://onco.cc/technologies/idh-inhibitors/), [LSD1 inhibitors](https://onco.cc/technologies/lsd1-inhibitors/), [MDM2 inhibitors](https://onco.cc/technologies/mdm2-inhibitors/), [Menin inhibitors](https://onco.cc/technologies/menin-inhibitors/), [Multiparameter flow cytometry MRD](https://onco.cc/technologies/flow-cytometry-mrd/), [NGS-based MRD (clonoSEQ and molecular MRD)](https://onco.cc/technologies/ngs-mrd-clonoseq/), [NK cell therapy and CAR-NK](https://onco.cc/technologies/nk-cell-therapy/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/), [TIM-3 blockade](https://onco.cc/technologies/tim3-blockade/), [Total body and total marrow irradiation](https://onco.cc/technologies/total-body-irradiation/), [Transfusion support and anaemia management](https://onco.cc/technologies/transfusion-support/)
- targets: [ACSL3](https://onco.cc/targets/acsl3/), [ASXL2](https://onco.cc/targets/asxl2/), [BAX](https://onco.cc/targets/bax/), [BCL-2](https://onco.cc/targets/bcl2/), [BCLAF1](https://onco.cc/targets/bclaf1/), [BCORL1](https://onco.cc/targets/bcorl1/), [BIM (BCL2L11)](https://onco.cc/targets/bim/), [CBL](https://onco.cc/targets/cbl/), [CCND2](https://onco.cc/targets/ccnd2/), [CCNT1](https://onco.cc/targets/ccnt1/), [CD123](https://onco.cc/targets/cd123/), [CD33](https://onco.cc/targets/cd33/), [CD47](https://onco.cc/targets/cd47/), [CD7](https://onco.cc/targets/cd7/), [CD70](https://onco.cc/targets/cd70/), [CEBPA](https://onco.cc/targets/cebpa/), [CSF2RB](https://onco.cc/targets/csf2rb/), [CXCR4](https://onco.cc/targets/cxcr4/), [DDB2](https://onco.cc/targets/ddb2/), [DDX41](https://onco.cc/targets/ddx41/), [DNA methyltransferase 3A (DNMT3A)](https://onco.cc/targets/dnmt3a/), [DNA polymerase alpha (POLA1)](https://onco.cc/targets/pola1/), [DNMT1 (DNA methyltransferase 1)](https://onco.cc/targets/dnmt1/), [ELF4](https://onco.cc/targets/elf4/), [ERCC4](https://onco.cc/targets/ercc4/), [ETV5](https://onco.cc/targets/etv5/), [FANCC](https://onco.cc/targets/fancc/), [FANCD2](https://onco.cc/targets/fancd2/), [FANCE](https://onco.cc/targets/fance/), [FANCG](https://onco.cc/targets/fancg/), [FGD5](https://onco.cc/targets/fgd5/), [FGF2](https://onco.cc/targets/fgf2/), [FLG](https://onco.cc/targets/flg/), [FLT3](https://onco.cc/targets/flt3/), [FLT3LG](https://onco.cc/targets/flt3lg/), [FOXO3](https://onco.cc/targets/foxo3/), [GATA1](https://onco.cc/targets/gata1/), [GATA2](https://onco.cc/targets/gata2/), [GM-CSF receptor (CSF2RA)](https://onco.cc/targets/csf2ra/), [HCAR3](https://onco.cc/targets/hcar3/), [HOXA9](https://onco.cc/targets/hoxa9/), [IDH1 / IDH2](https://onco.cc/targets/idh/), [IMPDH1](https://onco.cc/targets/impdh1/), [KIR2DL1 (inhibitory KIR)](https://onco.cc/targets/kir2dl1/), [KMT2A (MLL) rearrangement](https://onco.cc/targets/kmt2a/), [LYN kinase](https://onco.cc/targets/lyn/), [MAML2](https://onco.cc/targets/maml2/), [MBD4](https://onco.cc/targets/mbd4/), [MDM2](https://onco.cc/targets/mdm2/), [MECOM](https://onco.cc/targets/mecom/), [MEIS1](https://onco.cc/targets/meis1/), [Menin](https://onco.cc/targets/menin/), [MPL (thrombopoietin receptor)](https://onco.cc/targets/mpl/), [MUC6](https://onco.cc/targets/muc6/), [MYH11](https://onco.cc/targets/myh11/), [NCAPH](https://onco.cc/targets/ncaph/), [NKTR](https://onco.cc/targets/nktr/), [NPM1 mutation](https://onco.cc/targets/npm1/), [NT5C3A](https://onco.cc/targets/nt5c3a/), [PCMTD1](https://onco.cc/targets/pcmtd1/), [PHF6](https://onco.cc/targets/phf6/), [PRDM1](https://onco.cc/targets/prdm1/), [PRKCB](https://onco.cc/targets/prkcb/), [PRKCD](https://onco.cc/targets/prkcd/), [PRKCE](https://onco.cc/targets/prkce/), [PRKCG](https://onco.cc/targets/prkcg/), [PRKCH](https://onco.cc/targets/prkch/), [PRKCI](https://onco.cc/targets/prkci/), [PRKCQ](https://onco.cc/targets/prkcq/), [PRKCZ](https://onco.cc/targets/prkcz/), [PRKD1](https://onco.cc/targets/prkd1/), [PRKD3](https://onco.cc/targets/prkd3/), [Protein kinase C family (PKC)](https://onco.cc/targets/pkc/), [RAD21](https://onco.cc/targets/rad21/), [RARB](https://onco.cc/targets/rarb/), [RARG](https://onco.cc/targets/rarg/), [Retinoic acid receptor alpha (RARA)](https://onco.cc/targets/rara/), [RPL5](https://onco.cc/targets/rpl5/), [RTEL1](https://onco.cc/targets/rtel1/), [SBDS](https://onco.cc/targets/sbds/), [SIRPA](https://onco.cc/targets/sirpa/), [SLC34A2](https://onco.cc/targets/slc34a2/), [SLX4](https://onco.cc/targets/slx4/), [SMC1A](https://onco.cc/targets/smc1a/), [Smoothened (hedgehog pathway)](https://onco.cc/targets/smoothened/), [SRSF2](https://onco.cc/targets/srsf2/), [STAG2-AS1](https://onco.cc/targets/stag2-as1/), [STAT5 (STAT5A, STAT5B)](https://onco.cc/targets/stat5/), [SUZ12](https://onco.cc/targets/suz12/), [TET2](https://onco.cc/targets/tet2/), [Thioredoxin reductase 1](https://onco.cc/targets/txnrd1/), [THRAP3](https://onco.cc/targets/thrap3/), [TIM-3](https://onco.cc/targets/tim3/), [TNC](https://onco.cc/targets/tnc/), [TP53](https://onco.cc/targets/tp53/), [U2AF2](https://onco.cc/targets/u2af2/), [UBTF](https://onco.cc/targets/ubtf/), [USP6](https://onco.cc/targets/usp6/), [WT1](https://onco.cc/targets/wt1/), [Xanthine oxidase (XDH)](https://onco.cc/targets/xdh/), [ZCRB1](https://onco.cc/targets/zcrb1/), [ZRSR2](https://onco.cc/targets/zrsr2/)
- drugs: [AK117](https://onco.cc/drugs/ak117/), [Allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq](https://onco.cc/drugs/tregzi/), [Aminopterin](https://onco.cc/drugs/aminopterin/), [Amsacrine](https://onco.cc/drugs/amsacrine/), [ARD103](https://onco.cc/drugs/ard103/), [Arsenic trioxide](https://onco.cc/drugs/arsenic-trioxide/), [Azacitidine](https://onco.cc/drugs/azacitidine/), [Belumosudil](https://onco.cc/drugs/belumosudil/), [Bexmarilimab](https://onco.cc/drugs/bexmarilimab/), [Bleximenib](https://onco.cc/drugs/bleximenib/), [CART84](https://onco.cc/drugs/cart84/), [Clifutinib](https://onco.cc/drugs/clifutinib/), [CPX-351 (liposomal daunorubicin-cytarabine)](https://onco.cc/drugs/cpx-351/), [Cusatuzumab](https://onco.cc/drugs/cusatuzumab/), [Cytarabine](https://onco.cc/drugs/cytarabine/), [Cytarabine + anthracycline ('7+3')](https://onco.cc/drugs/cytarabine-7-3/), [Daunorubicin](https://onco.cc/drugs/daunorubicin/), [Decitabine](https://onco.cc/drugs/decitabine/), [Decitabine + cedazuridine (oral)](https://onco.cc/drugs/decitabine-cedazuridine/), [Dorocubicel (UM171-expanded cord blood)](https://onco.cc/drugs/dorocubicel/), [Eltrombopag](https://onco.cc/drugs/eltrombopag/), [Enasidenib](https://onco.cc/drugs/enasidenib/), [Eprenetapopt](https://onco.cc/drugs/eprenetapopt/), [Etoposide](https://onco.cc/drugs/etoposide/), [Gemtuzumab ozogamicin](https://onco.cc/drugs/gemtuzumab-ozogamicin/), [Gilteritinib](https://onco.cc/drugs/gilteritinib/), [Glasdegib](https://onco.cc/drugs/glasdegib/), [Histamine dihydrochloride](https://onco.cc/drugs/histamine-dihydrochloride/), [HMPL-306](https://onco.cc/drugs/hmpl-306/), [Idarubicin](https://onco.cc/drugs/idarubicin/), [Iomab-B](https://onco.cc/drugs/iomab-b/), [Ivosidenib](https://onco.cc/drugs/ivosidenib/), [Magrolimab](https://onco.cc/drugs/magrolimab/), [Midostaurin](https://onco.cc/drugs/midostaurin/), [Mitoxantrone](https://onco.cc/drugs/mitoxantrone/), [Olutasidenib](https://onco.cc/drugs/olutasidenib/), [Omidubicel](https://onco.cc/drugs/omidubicel/), [Pivekimab sunirine](https://onco.cc/drugs/pivekimab-sunirine/), [Quizartinib](https://onco.cc/drugs/quizartinib/), [Rasburicase](https://onco.cc/drugs/rasburicase/), [Revumenib](https://onco.cc/drugs/revumenib/), [Romiplostim](https://onco.cc/drugs/romiplostim/), [RVU120](https://onco.cc/drugs/rvu120/), [Sargramostim](https://onco.cc/drugs/sargramostim/), [Tagraxofusp](https://onco.cc/drugs/tagraxofusp/), [Thioguanine](https://onco.cc/drugs/thioguanine/), [Treosulfan](https://onco.cc/drugs/treosulfan/), [Tretinoin (all-trans retinoic acid, ATRA)](https://onco.cc/drugs/tretinoin-atra/), [Venetoclax](https://onco.cc/drugs/venetoclax/), [Ziftomenib](https://onco.cc/drugs/ziftomenib/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/), [Actinium Pharmaceuticals](https://onco.cc/companies/actinium-pharmaceuticals/), [ALFA (Acute Leukemia French Association)](https://onco.cc/companies/alfa/), [Allotera Therapeutics (formerly Wugen)](https://onco.cc/companies/allotera-therapeutics/), [Amphista Therapeutics](https://onco.cc/companies/amphista-therapeutics/), [Apollomics](https://onco.cc/companies/apollomics/), [Aprea Therapeutics](https://onco.cc/companies/aprea-therapeutics/), [Aptose Biosciences](https://onco.cc/companies/aptose/), [argenx](https://onco.cc/companies/argenx/), [Arog Pharmaceuticals](https://onco.cc/companies/arog-pharmaceuticals/), [Ascentage Pharma](https://onco.cc/companies/ascentage-pharma/), [Astellas](https://onco.cc/companies/astellas/), [Beckman Coulter](https://onco.cc/companies/beckman-coulter/), [Bellicum Pharmaceuticals](https://onco.cc/companies/bellicum/), [Bristol Myers Squibb](https://onco.cc/companies/bms/), [Cellectis](https://onco.cc/companies/cellectis/), [Cornerstone Pharmaceuticals (formerly Rafael Pharmaceuticals)](https://onco.cc/companies/cornerstone-pharmaceuticals/), [Cullinan Therapeutics](https://onco.cc/companies/cullinan-therapeutics/), [Cyclacel Pharmaceuticals](https://onco.cc/companies/cyclacel/), [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/), [Delta-Fly Pharma](https://onco.cc/companies/delta-fly-pharma/), [Ellipses Pharma](https://onco.cc/companies/ellipses-pharma/), [FILO (French Innovative Leukemia Organisation)](https://onco.cc/companies/filo/), [Gamida Cell](https://onco.cc/companies/gamida-cell/), [GIMEMA](https://onco.cc/companies/gimema/), [HOVON](https://onco.cc/companies/hovon/), [Jazz Pharmaceuticals](https://onco.cc/companies/jazz/), [JW Pharmaceutical](https://onco.cc/companies/jw-pharmaceutical/), [Kura Oncology](https://onco.cc/companies/kura-oncology/), [medac](https://onco.cc/companies/medac/), [Medigene](https://onco.cc/companies/medigene/), [MEI Pharma](https://onco.cc/companies/mei-pharma/), [Mendus](https://onco.cc/companies/mendus/), [Miltenyi Biomedicine](https://onco.cc/companies/miltenyi-biomedicine/), [Mission Bio](https://onco.cc/companies/mission-bio/), [Molecular Partners](https://onco.cc/companies/molecular-partners/), [Moleculin Biotech](https://onco.cc/companies/moleculin/), [Neovii](https://onco.cc/companies/neovii/), [Nkarta](https://onco.cc/companies/nkarta/), [Notable Labs](https://onco.cc/companies/notable-labs/), [Novartis](https://onco.cc/companies/novartis/), [OncoVerity](https://onco.cc/companies/oncoverity/), [Orca Bio](https://onco.cc/companies/orca-bio/), [Orum Therapeutics](https://onco.cc/companies/orum-therapeutics/), [Otsuka Pharmaceutical](https://onco.cc/companies/otsuka/), [Partner Therapeutics](https://onco.cc/companies/partner-therapeutics/), [Rigel Pharmaceuticals](https://onco.cc/companies/rigel-pharmaceuticals/), [Ryvu Therapeutics](https://onco.cc/companies/ryvu-therapeutics/), [Servier](https://onco.cc/companies/servier/), [Shenzhen TargetRx](https://onco.cc/companies/shenzhen-targetrx/), [SonALAsense](https://onco.cc/companies/sonalasense/), [Sunesis Pharmaceuticals](https://onco.cc/companies/sunesis/), [Sunshine Lake Pharma (HEC)](https://onco.cc/companies/sunshine-lake-pharma/), [Syndax Pharmaceuticals](https://onco.cc/companies/syndax/), [Taiho Oncology (Otsuka)](https://onco.cc/companies/taiho-oncology/), [Treadwell Therapeutics](https://onco.cc/companies/treadwell-therapeutics/), [Unicar-Therapy](https://onco.cc/companies/unicar-therapy/), [Vion Pharmaceuticals](https://onco.cc/companies/vion-pharmaceuticals/), [Vor Biopharma](https://onco.cc/companies/vor-biopharma/)
- pathways: [Acute myeloid leukaemia (KEGG map)](https://onco.cc/pathways/aml-signalling/), [CD47 / SIRPα (the 'don't eat me' signal)](https://onco.cc/pathways/cd47-sirpa/), [Clonal haematopoiesis (CHIP)](https://onco.cc/pathways/clonal-haematopoiesis/), [Hedgehog signalling](https://onco.cc/pathways/hedgehog/), [Intrinsic apoptosis (BCL-2 family)](https://onco.cc/pathways/apoptosis-bcl2/), [Menin / KMT2A (HOXA9-MEIS1 axis)](https://onco.cc/pathways/menin-kmt2a/), [Mutant IDH / 2-hydroxyglutarate](https://onco.cc/pathways/idh-2hg/), [RNA splicing](https://onco.cc/pathways/rna-splicing/), [Transcriptional machinery & addiction](https://onco.cc/pathways/transcription-addiction/)
- terms: [7+3 induction chemotherapy](https://onco.cc/terms/seven-plus-three/), [Ageing tissue and clonal fields: cancer as a disease of old tissue](https://onco.cc/terms/ageing-tissue-field-theory/), [Allogeneic stem cell transplant (allo-SCT)](https://onco.cc/terms/allogeneic-transplant/), [AML with myelodysplasia-related gene mutations (AML-MR)](https://onco.cc/terms/aml-myelodysplasia-related/), [Anthracyclines (doxorubicin, epirubicin)](https://onco.cc/terms/anthracycline/), [Blasts (leukaemic blast cells)](https://onco.cc/terms/blasts/), [Cancer stem cell theory and phenotypic plasticity](https://onco.cc/terms/cancer-stem-cell-theory/), [Consolidation therapy](https://onco.cc/terms/consolidation-therapy/), [Cytogenetics and karyotype](https://onco.cc/terms/cytogenetics/), [Differentiation syndrome](https://onco.cc/terms/differentiation-syndrome/), [ELN 2022 risk classification](https://onco.cc/terms/eln-risk/), [Epigenetic progenitor theory: cancer without a first mutation](https://onco.cc/terms/epigenetic-progenitor-theory/), [Flow cytometry (immunophenotyping)](https://onco.cc/terms/flow-cytometry/), [FLT3-ITD allelic ratio](https://onco.cc/terms/flt3-itd-allelic-ratio/), [Hypomethylating agents (azacitidine, decitabine)](https://onco.cc/terms/hma/), [Induction therapy](https://onco.cc/terms/induction-therapy/), [Leukaemia (tissue type)](https://onco.cc/terms/leukaemia-type/), [Metabolic theory of cancer: from Warburg to oncometabolites](https://onco.cc/terms/metabolic-theory-of-cancer/), [MRD-negative complete remission](https://onco.cc/terms/mrd-negative-cr/), [TP53-mutated (p53-abnormal)](https://onco.cc/terms/tp53-mutated/), [Tumour lysis syndrome (TLS)](https://onco.cc/terms/tumor-lysis-syndrome/), [Undetectable MRD (uMRD / MRD-negative)](https://onco.cc/terms/umrd/)
- trials: [A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies](https://onco.cc/trials/nct05589896/), [A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML](https://onco.cc/trials/nct03591510/), [A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)](https://onco.cc/trials/nct04256317/), [A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia](https://onco.cc/trials/nct07623616/), [A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia](https://onco.cc/trials/nct07743112/), [A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML](https://onco.cc/trials/nct05133882/), [A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia](https://onco.cc/trials/nct06389292/), [A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation](https://onco.cc/trials/nct03182244/), [A Study of BGB-11417 in Participants With Myeloid Malignancies](https://onco.cc/trials/nct04771130/), [A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia](https://onco.cc/trials/nct07255872/), [A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)](https://onco.cc/trials/nct06852222/), [A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes](https://onco.cc/trials/nct05732103/), [A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy](https://onco.cc/trials/nct04023526/), [A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia](https://onco.cc/trials/nct05520567/), [A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy](https://onco.cc/trials/nct06456463/), [A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)](https://onco.cc/trials/nct07581002/), [A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies](https://onco.cc/trials/nct05428969/), [A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy](https://onco.cc/trials/nct02677922/), [A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)](https://onco.cc/trials/nct06969430/), [A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations](https://onco.cc/trials/nct04293562/), [A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission](https://onco.cc/trials/nct05197426/), [A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia](https://onco.cc/trials/nct06387069/), [A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia](https://onco.cc/trials/nct04980885/), [AAML1031](https://onco.cc/trials/aaml1031/), [AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia](https://onco.cc/trials/nct05211570/), [Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies](https://onco.cc/trials/nct07523555/), [ADMIRAL](https://onco.cc/trials/admiral/), [AGILE](https://onco.cc/trials/agile/), [ALFA-0701](https://onco.cc/trials/alfa-0701/), [An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission](https://onco.cc/trials/nct05413018/), [An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.](https://onco.cc/trials/nct05907057/), [APL0406](https://onco.cc/trials/apl0406/), [ASCERTAIN-V](https://onco.cc/trials/ascertain-v/), [AUGMENT-101](https://onco.cc/trials/augment-101/), [Beat AML Master Trial](https://onco.cc/trials/beat-aml-master-trial/), [Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)](https://onco.cc/trials/nct00822393/), [Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS](https://onco.cc/trials/nct06680752/), [Clinical Study of U32 in Patients With Acute Myeloid Leukemia](https://onco.cc/trials/nct07036250/), [Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML](https://onco.cc/trials/nct02781883/), [Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia](https://onco.cc/trials/nct00703820/), [COG AAML0531](https://onco.cc/trials/aaml0531/), [Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML](https://onco.cc/trials/nct04842604/), [CPX-351 Study 301](https://onco.cc/trials/cpx-351-301/), [DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia](https://onco.cc/trials/nct06382168/), [Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission](https://onco.cc/trials/nct06824168/), [First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients](https://onco.cc/trials/nct05601726/), [Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2](https://onco.cc/trials/nct04229979/), [Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)](https://onco.cc/trials/nct04093505/), [HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML](https://onco.cc/trials/nct05586074/), [IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia](https://onco.cc/trials/nct04086264/), [KOMET-001](https://onco.cc/trials/komet-001/), [L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Re](https://onco.cc/trials/nct06788756/), [Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT](https://onco.cc/trials/nct05429632/), [MORPHO](https://onco.cc/trials/morpho/), [myeloMATCH](https://onco.cc/trials/myelomatch/), [PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS](https://onco.cc/trials/nct07761533/), [Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia](https://onco.cc/trials/nct06118788/), [Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies](https://onco.cc/trials/nct05316701/), [QuANTUM-First](https://onco.cc/trials/quantum-first/), [QUAZAR AML-001](https://onco.cc/trials/quazar-aml-001/), [RATIFY (CALGB 10603)](https://onco.cc/trials/ratify/), [Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome](https://onco.cc/trials/nct02521493/), [Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia](https://onco.cc/trials/nct02072811/), [Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).](https://onco.cc/trials/nct07471789/), [Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors](https://onco.cc/trials/nct03934372/), [Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood](https://onco.cc/trials/nct03793478/), [Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML](https://onco.cc/trials/nct06191263/), [Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML](https://onco.cc/trials/nct07007312/), [Study 0201](https://onco.cc/trials/study-0201/), [Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT](https://onco.cc/trials/nct05917405/), [Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy](https://onco.cc/trials/nct03603795/), [Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients](https://onco.cc/trials/nct05433532/), [Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression](https://onco.cc/trials/nct07155226/), [Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant](https://onco.cc/trials/nct03301168/), [Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia](https://onco.cc/trials/nct02665065/), [Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML](https://onco.cc/trials/nct04501120/), [Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated](https://onco.cc/trials/nct04778397/), [Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia](https://onco.cc/trials/nct05079230/), [Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome](https://onco.cc/trials/nct05673057/), [Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation](https://onco.cc/trials/nct07211958/), [Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy](https://onco.cc/trials/nct05583552/), [Study to Evaluate the Safety and Tolerability of EP0042](https://onco.cc/trials/nct04581512/), [TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies](https://onco.cc/trials/nct06206174/), [VIALE-A](https://onco.cc/trials/viale-a/)
- people: [Aaron D. Schimmer](https://onco.cc/people/aaron-schimmer/), [Adrian Ochsenbein](https://onco.cc/people/adrian-ochsenbein/), [Akifumi Takaori](https://onco.cc/people/akifumi-takaori/), [Alexander E. Perl](https://onco.cc/people/alexander-perl/), [Andrew H. Wei](https://onco.cc/people/andrew-wei/), [Anthony Letai](https://onco.cc/people/anthony-letai/), [Benjamin L. Ebert](https://onco.cc/people/benjamin-ebert/), [Brian Huntly](https://onco.cc/people/brian-huntly/), [Cheryl L. Willman](https://onco.cc/people/cheryl-willman/), [Christian Brandts](https://onco.cc/people/christian-brandts/), [Christopher R. Vakoc](https://onco.cc/people/christopher-vakoc/), [Courtney D. DiNardo](https://onco.cc/people/courtney-dinardo/), [Emil J Freireich](https://onco.cc/people/emil-freireich/), [Eunice S. Wang](https://onco.cc/people/eunice-wang/), [Eytan M. Stein](https://onco.cc/people/eytan-stein/), [Francesco Lo-Coco](https://onco.cc/people/francesco-lo-coco/), [Ghayas C. Issa](https://onco.cc/people/ghayas-issa/), [Hagop M. Kantarjian](https://onco.cc/people/hagop-kantarjian/), [Hans-Peter Kiem](https://onco.cc/people/hans-peter-kiem/), [Hartmut Döhner](https://onco.cc/people/hartmut-dohner/), [Hervé Dombret](https://onco.cc/people/herve-dombret/), [Hubert Serve](https://onco.cc/people/hubert-serve/), [Irving L. Weissman](https://onco.cc/people/irving-weissman/), [James R. Downing](https://onco.cc/people/james-r-downing/), [Janet Rowley](https://onco.cc/people/janet-rowley/), [Jaroslaw P. Maciejewski](https://onco.cc/people/jaroslaw-maciejewski/), [Jeffrey E. Lancet](https://onco.cc/people/jeffrey-lancet/), [John E. Dick](https://onco.cc/people/john-dick/), [John F. DiPersio](https://onco.cc/people/john-dipersio/), [Jürgen Kuball](https://onco.cc/people/jurgen-kuball/), [Konstanze Döhner](https://onco.cc/people/konstanze-doehner/), [Lars Bullinger](https://onco.cc/people/lars-bullinger/), [Marc H.G.P. Raaijmakers](https://onco.cc/people/marc-raaijmakers/), [Marco Vignetti](https://onco.cc/people/marco-vignetti/), [Martin Bornhäuser](https://onco.cc/people/martin-bornhauser/), [Michael A. Caligiuri](https://onco.cc/people/michael-caligiuri/), [Miguel A. Sanz](https://onco.cc/people/miguel-sanz/), [Nicolaas P.M. Schaap](https://onco.cc/people/nicolaas-schaap/), [Norbert Vey](https://onco.cc/people/norbert-vey/), [Philip D. Greenberg](https://onco.cc/people/philip-greenberg/), [Pier Giuseppe Pelicci](https://onco.cc/people/pier-giuseppe-pelicci/), [Pierre Fenaux](https://onco.cc/people/pierre-fenaux/), [Richard M. Stone](https://onco.cc/people/richard-stone/), [Ross L. Levine](https://onco.cc/people/ross-levine/), [Saijuan Chen](https://onco.cc/people/chen-saijuan/), [Stephen B. Baylin](https://onco.cc/people/stephen-baylin/), [Stephen J. Forman](https://onco.cc/people/stephen-forman/), [Susan Love](https://onco.cc/people/susan-love/), [Thomas Kindler](https://onco.cc/people/thomas-kindler/), [Tim Somervaille](https://onco.cc/people/tim-somervaille/), [Timothy J. Ley](https://onco.cc/people/timothy-ley/), [Todd R. Golub](https://onco.cc/people/todd-golub/), [Uwe Platzbecker](https://onco.cc/people/uwe-platzbecker/), [Xiaojun Huang](https://onco.cc/people/huang-xiaojun/), [Zhu Chen](https://onco.cc/people/chen-zhu/)
- journals: [Blood cancer discovery](https://onco.cc/journals/blood-cancer-discovery/), [Blood cancer journal](https://onco.cc/journals/blood-cancer-journal/), [Clinical lymphoma, myeloma & leukemia](https://onco.cc/journals/clinical-lymphoma-myeloma-and-leukemia/), [Current hematologic malignancy reports](https://onco.cc/journals/current-hematologic-malignancy-reports/), [Haematologica](https://onco.cc/journals/haematologica/), [Hematology/oncology and stem cell therapy](https://onco.cc/journals/hematology-oncology-and-stem-cell-therapy/), [Journal of hematology & oncology](https://onco.cc/journals/journal-of-hematology-and-oncology/), [Leukemia & lymphoma](https://onco.cc/journals/leukemia-and-lymphoma/), [Leukemia research](https://onco.cc/journals/leukemia-research/)
- pairings: [FLT3 inhibitor + intensive chemotherapy](https://onco.cc/pairings/flt3i-plus-7-3/), [Menin inhibitor + venetoclax + azacitidine](https://onco.cc/pairings/menin-plus-venetoclax-hma/), [Venetoclax + hypomethylating agent](https://onco.cc/pairings/venetoclax-plus-hma/)
- ideas: [Automated combination discovery: patient-sample screens feeding Bayesian platform trials](https://onco.cc/ideas/idea-moon-automated-combination-discovery/), [Dose-finding in older and frail patients, not extrapolation from fit ones](https://onco.cc/ideas/idea-tr1-geriatric-dose-finding-cohorts/), [MRD-guided transplant decisions in intermediate-risk AML](https://onco.cc/ideas/idea-mrd-guided-transplant-aml/), [Shared splice-derived neoantigens as off-the-shelf vaccine targets](https://onco.cc/ideas/idea-splice-neoantigens/), [Shorter venetoclax courses in unfit AML](https://onco.cc/ideas/idea-shortened-venetoclax/), [Starve the survivors: target the energy pathway drug-tolerant cells switch to](https://onco.cc/ideas/idea-bio1-persister-metabolic-vulnerability/), [Which patients' blood clones will become leukaemia after treatment?](https://onco.cc/ideas/idea-chip-risk-modifiers/)
- bottlenecks: [Dormant cells and minimal residual disease](https://onco.cc/bottlenecks/b-dormancy-mrd/), [Older and multimorbid patients are excluded and undertreated](https://onco.cc/bottlenecks/b-aging-comorbidity/), [The undruggable drivers](https://onco.cc/bottlenecks/b-undruggable-targets/), [Wrong doses](https://onco.cc/bottlenecks/b-dose-optimisation/)
- collections: [Leukemia & Lymphoma Society (LLS)](https://onco.cc/collections/leukemia-lymphoma-society/)
- key papers: [AAML1031: bortezomib with standard chemotherapy for children with acute myeloid leukaemia does not improve outcomes](https://onco.cc/key-papers/paper-aaml1031-bortezomib-aplenc-haematologica-2020/), [ADMIRAL: gilteritinib pills versus chemotherapy for relapsed FLT3-mutated acute myeloid leukaemia](https://onco.cc/key-papers/paper-admiral-gilteritinib-flt3-nejm-2019/), [AGILE: ivosidenib plus azacitidine for newly diagnosed IDH1-mutated AML in patients unfit for intensive chemotherapy](https://onco.cc/key-papers/paper-agile-ivosidenib-azacitidine-nejm-2022/), [AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation](https://onco.cc/key-papers/paper-augment-101-revumenib-menin-nature-2023/), [Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial](https://onco.cc/key-papers/paper-study-0201-blood-2006/), [Jaiswal: clonal haematopoiesis, the pre-leukaemic clones in most people over 70](https://onco.cc/key-papers/paper-jaiswal-chip-nejm-2014/), [MORPHO: gilteritinib as post-transplant maintenance for FLT3-ITD acute myeloid leukaemia](https://onco.cc/key-papers/paper-morpho-gilteritinib-levis-jco-2024/), [QuANTUM-First: quizartinib added to intensive chemotherapy and continued as maintenance in newly diagnosed FLT3-ITD AML](https://onco.cc/key-papers/paper-quantum-first-quizartinib-lancet-2023/), [QUAZAR AML-001: oral azacitidine maintenance for acute myeloid leukaemia in first remission](https://onco.cc/key-papers/paper-quazar-aml-001-wei-nejm-2020/), [Reya 2001: stem cells, cancer and cancer stem cells](https://onco.cc/key-papers/paper-reya-cancer-stem-cells-nature-2001/), [VIALE-A: venetoclax plus azacitidine for older adults with acute myeloid leukaemia who cannot have intensive chemotherapy](https://onco.cc/key-papers/paper-viale-a-venetoclax-azacitidine-nejm-2020/)
- institutions: [American Society of Hematology](https://onco.cc/institutions/ash/), [Auckland City Hospital / Te Pūriri o Te Ora Cancer and Blood Service](https://onco.cc/institutions/auckland-city-hospital/), [Cancer Institute AP-HP Nord, Université Paris Cité](https://onco.cc/institutions/aphp-nord-cancer-institute/), [Cancer Research UK Manchester Institute](https://onco.cc/institutions/cruk-manchester-institute/), [Chao Family Comprehensive Cancer Center, UC Irvine](https://onco.cc/institutions/uci-chao/), [Children's Cancer Hospital Egypt 57357](https://onco.cc/institutions/cche-57357/), [Chinese PLA General Hospital](https://onco.cc/institutions/pla-general-hospital/), [Christian Medical College, Vellore](https://onco.cc/institutions/cmc-vellore/), [Comprehensive Cancer Center Freiburg (CCCF)](https://onco.cc/institutions/ccc-freiburg/), [Comprehensive Cancer Center Mainfranken, University Hospital Würzburg](https://onco.cc/institutions/ccc-wuerzburg/), [Comprehensive Cancer Center Tübingen-Stuttgart](https://onco.cc/institutions/ccc-tuebingen/), [European Hematology Association](https://onco.cc/institutions/eha/), [Great Ormond Street Hospital for Children](https://onco.cc/institutions/great-ormond-street/), [Hamad Medical Corporation / National Center for Cancer Care and Research](https://onco.cc/institutions/hamad-medical-corporation/), [Hôpital Maisonneuve-Rosemont / CIUSSS de l'Est-de-l'Île-de-Montréal](https://onco.cc/institutions/ciusss-emtl-maisonneuve-rosemont/), [Hospital Universitari i Politècnic La Fe](https://onco.cc/institutions/la-fe-valencia/), [Hospital Universitario 12 de Octubre](https://onco.cc/institutions/12-de-octubre/), [HUS Comprehensive Cancer Center, Helsinki University Hospital](https://onco.cc/institutions/helsinki-hus/), [Institut Paoli-Calmettes](https://onco.cc/institutions/institut-paoli-calmettes/), [Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences](https://onco.cc/institutions/cams-hematology/), [IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola](https://onco.cc/institutions/sant-orsola-bologna/), [IRCCS Ospedale San Raffaele](https://onco.cc/institutions/san-raffaele/), [Kyoto University Hospital](https://onco.cc/institutions/kyoto-university-hospital/), [Masonic Cancer Center, University of Minnesota](https://onco.cc/institutions/minnesota-masonic/), [Montefiore Einstein Comprehensive Cancer Center](https://onco.cc/institutions/montefiore-einstein/), [National Taiwan University Hospital](https://onco.cc/institutions/ntuh/), [National University Hospital / National University Cancer Institute, Singapore](https://onco.cc/institutions/nuh-ncis/), [NCT/UCC Dresden, University Hospital Carl Gustav Carus](https://onco.cc/institutions/nct-dresden/), [OHSU Knight Cancer Institute](https://onco.cc/institutions/ohsu-knight/), [Oxford Cancer (Oxford University Hospitals and University of Oxford)](https://onco.cc/institutions/oxford-cancer/), [Peking University People's Hospital](https://onco.cc/institutions/pku-peoples-hospital/), [Princess Máxima Center for Pediatric Oncology](https://onco.cc/institutions/princess-maxima/), [Queen Mary Hospital / University of Hong Kong](https://onco.cc/institutions/queen-mary-hospital-hku/), [Ramathibodi Hospital, Mahidol University](https://onco.cc/institutions/ramathibodi-hospital/), [Rambam Health Care Campus](https://onco.cc/institutions/rambam/), [Rigshospitalet, Copenhagen University Hospital](https://onco.cc/institutions/rigshospitalet/), [Royal Adelaide Hospital](https://onco.cc/institutions/royal-adelaide-hospital/), [Ruijin Hospital, Shanghai Jiao Tong University](https://onco.cc/institutions/ruijin-hospital/), [Seoul St. Mary's Hospital](https://onco.cc/institutions/seoul-st-marys-hospital/), [Siriraj Hospital, Mahidol University](https://onco.cc/institutions/siriraj-hospital/), [Sylvester Comprehensive Cancer Center, University of Miami](https://onco.cc/institutions/sylvester-miami/), [Tata Medical Center, Kolkata](https://onco.cc/institutions/tata-medical-center-kolkata/), [The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute](https://onco.cc/institutions/osu-james/), [Ulm University Hospital / Comprehensive Cancer Center Ulm](https://onco.cc/institutions/ulm-university-hospital/), [University Cancer Center Frankfurt (UCT)](https://onco.cc/institutions/uct-frankfurt/), [USC Norris Comprehensive Cancer Center](https://onco.cc/institutions/usc-norris/), [VCU Massey Comprehensive Cancer Center](https://onco.cc/institutions/vcu-massey/), [Walter and Eliza Hall Institute of Medical Research](https://onco.cc/institutions/wehi/), [Weizmann Institute of Science](https://onco.cc/institutions/weizmann/), [West German Cancer Center (WTZ), University Hospital Essen](https://onco.cc/institutions/essen-wtz/)
- biomarkers: [CD33 expression (CD33-positive)](https://onco.cc/biomarkers/cd33-expression/), [FLT3-ITD (internal tandem duplication)](https://onco.cc/biomarkers/flt3-itd/), [FLT3-TKD (D835 and I836 tyrosine kinase domain mutations)](https://onco.cc/biomarkers/flt3-tkd/), [IDH1 R132 mutation](https://onco.cc/biomarkers/idh1-r132/), [IDH2 mutation (R140 and R172)](https://onco.cc/biomarkers/idh2-mutation/), [KIT D816V](https://onco.cc/biomarkers/kit-d816v/), [NPM1 mutation](https://onco.cc/biomarkers/npm1-mutation/), [TP53 mutation and del(17p)](https://onco.cc/biomarkers/tp53-del17p/)

---
JSON: https://onco.cc/api/v1/entities/aml.json